| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Lucira Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$1.45 |
| 52 Week Low | US$0.000001 |
| Beta | 2.39 |
| 1 Month Change | -50.00% |
| 3 Month Change | -99.44% |
| 1 Year Change | -99.99% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Lucira Health reports early data for point of care chlamydia and gonorrhea assays
Sep 29Lucira COVID & Flu test gets emergency use authorization from Health Canada
Aug 11Lucira Health Sees Strong Revenue Growth But Needs More Cash
Mar 10Analysts' Revenue Estimates For Lucira Health, Inc. (NASDAQ:LHDX) Are Surging Higher
Nov 25
Is Lucira Health (NASDAQ:LHDX) In A Good Position To Invest In Growth?
Jun 29Lucira Health appoints medtech veteran Kevin Collins as CRO
May 28Health Canada issues 'authorization with conditions' for Lucira's COVID-19 test kit
Apr 26Shareholder Returns
| LHDX.Q | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 1.2% |
| 1Y | -100.0% | -0.5% | 24.9% |
Return vs Industry: LHDX.Q underperformed the US Medical Equipment industry which returned -1.8% over the past year.
Return vs Market: LHDX.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| LHDX.Q volatility | |
|---|---|
| LHDX.Q Average Weekly Movement | 2,860.0% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LHDX.Q's share price has been volatile over the past 3 months.
Volatility Over Time: LHDX.Q's weekly volatility has increased from 1417% to 2860% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 221 | n/a | www.lucirahealth.com |
Lucira Health, Inc. is in the process of liquidation. Previously, the company engaged in the development and commercialization of infectious disease test kits. It developed a testing platform that produces molecular testing services.
Lucira Health, Inc. Fundamentals Summary
| LHDX.Q fundamental statistics | |
|---|---|
| Market cap | US$4.18k |
| Earnings (TTM) | -US$143.28m |
| Revenue (TTM) | US$212.13m |
0.0x
P/S Ratio0.0x
P/E RatioIs LHDX.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LHDX.Q income statement (TTM) | |
|---|---|
| Revenue | US$212.13m |
| Cost of Revenue | US$251.34m |
| Gross Profit | -US$39.20m |
| Other Expenses | US$104.07m |
| Earnings | -US$143.28m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.43 |
| Gross Margin | -18.48% |
| Net Profit Margin | -67.54% |
| Debt/Equity Ratio | 48.3% |
How did LHDX.Q perform over the long term?
See historical performance and comparison